Serum procalcitonin as a marker of renal allograft function in the immediate post-transplant period
PDF (Español)
XML-JATS (Español)


Early renal allograft failure
Renal Transplant

How to Cite

Ramírez Flores D, Andrade-Sierra J, Rojas-Campos E, Evangelista-Carrillo LA, Heredia-Pimentel A, Montañez-Fernández JL, Pazarín-Villaseñor L, Cerrillos-Gutiérrez JI. Serum procalcitonin as a marker of renal allograft function in the immediate post-transplant period. Rev. Colomb. Nefrol. [Internet]. 2022 Aug. 29 [cited 2024 Jul. 16];9(2). Available from:


Background: Procalcitonin (PCT) could be useful for evaluation of the renal allograft (RG) in the immediate post-transplant since its levels increase after elevation of the inflammatory cytokines (IL-6, TNF-?) during events of renal failure.

Purpose: Our objective was to determine the association of serum PCT with the function of the RG in the immediate post-transplant.

Methodology: A retrospective cohort from September 2018- April 2019 in the National Western Medical Center of the Mexican Social Security Institute (IMSS), was performed. Sixty-two recipients of living donor (LD) and deceased donor (DD) renal transplant (RT) with PCT evaluation in the first seven days of RT were included; and, events of early renal allograft failure (EAF) were recorded and compared to patients no EAF (nEAF).

Results: The recipients with EAF presented with higher PCT levels (13.90, 3.90, 1.22 ng/mL) compared to the nEAF group (0.32, 0.31, and 0.22 ng/ml) on days 1, 3, and 5, respectively (p < 0.05).

Conclusions: The PCT is a biological marker associated with EAF in the immediate post-transplant.
PDF (Español)
XML-JATS (Español)


Josephson MA. Monitoring and managing graft health in the kidney transplant recipient. Clin J Am Soc Nephrol. 2011;6(7):1774-80.

Striz I, Jaresova M, Lacha J, Sedlacek J, Vitko S. MRP 8/14 and procalcitonin serum levels in organ transplantations. Ann Transplant. 2001;6(2):6-9.

Araujo M, Doi SQ, Palant CE, Nylen ES, Becker KL. Procalcitonin induced cytotoxicity and apoptosis in mesangial cells: implications for septic renal injury. Inflamm Res. 2013;62(10):887-94.

Eberhard OK, Langefeld I, Kuse ER, Brunkhorst FM, Kliem V, Schlitt HJ, et al. Procalcitonin in the early phase after renal transplantation-will it add to diagnostic accuracy? Clin Transplant. 1998;12(3):206-11.

van Ree RM, de Vries AP, Oterdoom LH, Seelen MA, Gansevoort RT, Schouten JP, et al. Plasma procalcitonin is an independent predictor of graft failure late after renal transplantation. Transplantation. 2009;88(2):279-87.

Wang CJ, Tuffaha A, Phadnis MA, Mahnken JD, Wetmore JB. Association of Slow Graft Function with Long-Term Outcomes in Kidney Transplant Recipients. Ann Transplant. 2018;23:224-31.

Mogulla MR, Bhattacharjya S, Clayton PA. Risk factors for and outcomes of delayed graft function in live donor kidney transplantation - a retrospective study. Transpl Int. 2019;32(11):1151-60.

Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263-73.

Azzini AM, Dorizzi RM, Sette P, Vecchi M, Coledan I, Righi E, et al. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. Ann Transl Med. 2020;8(9):610.

Nieuwenhuijs-Moeke GJ, Pischke SE, Berger SP, Sanders JS, Pol RA, Struys M, et al. Ischemia and Reperfusion Injury in Kidney Transplantation: Relevant Mechanisms in Injury and Repair. J Clin Med. 2020;9(1).

Becker KL, Nylen ES, White JC, Muller B, Snider RH. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis, a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89(4):1512-25.

Level C, Chauveau P, Delmas Y, Lasseur C, Pelle G, Peuchant E, et al. Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant. 2001;16(5):980-6.

Grace E, Turner RM. Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy. Clin Infect Dis. 2014;59(12):1761-7.

Fadel FI, Elshamaa MF, Elghoroury EA, Badr AM, Kamel S, El-Sonbaty MM, et al. Usefulness of serum procalcitonin as a diagnostic biomarker of infection in children with chronic kidney disease. Arch Med Sci Atheroscler Dis. 2016;1(1):e23-31.

Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation. 2005;79(5):505-14.

Wagner FD, Jonitz B, Potapov EV, Qedra N, Wegscheider K, Abraham K, et al. Procalcitonin, a donor-specific predictor of early graft failure-related mortality after heart transplantation. Circulation. 2001;104(12):I192-6.

Jung DY, Park JB, Lee EN, Lee HA, Joh JW, Kwon CH, et al. Combined use of myeloid-related protein 8/14 and procalcitonin as diagnostic markers for acute allograft rejection in kidney transplantation recipients. Transpl Immunol. 2008;18(4):338-43.

Schiavelli RJ, Di Tullio D, Gautos A, Sabbatiello R, Pattin M, Ran?o M. Delayed graft function in kidney transplant recipients. Nefrol Dia?l Traspl. 2015;35(4):182-7.

Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transpl. 2011;11(11):2279-96.

Yarlagadda SG, Coca SG, Formica RN, Jr Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24(3):1039-47.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.




Download data is not yet available.